DrugPatentWatch Database Preview
XERMELO Drug Profile
When do Xermelo patents expire, and when can generic versions of Xermelo launch?
Xermelo is a drug marketed by Lexicon Pharms Inc and is included in one NDA. There are five patents protecting this drug.
This drug has sixty patent family members in twenty-eight countries.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this compound. Additional details are available on the telotristat etiprate profile page.
Summary for XERMELO
| International Patents: | 60 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 36 |
| Clinical Trials: | 3 |
| Patent Applications: | 27 |
| Drug Prices: | Drug price information for XERMELO |
| DailyMed Link: | XERMELO at DailyMed |
Generic Entry Opportunity Date for XERMELO
Generic Entry Date for XERMELO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for XERMELO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ipsen | Phase 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Emory University | Phase 2 |
Pharmacology for XERMELO
| Drug Class | Tryptophan Hydroxylase Inhibitor |
| Mechanism of Action | Tryptophan Hydroxylase Inhibitors |
Synonyms for XERMELO
| (S)-Ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate |
| 1033805-22-9 |
| 3791AH |
| 8G388563M7 |
| ABP000310 |
| AKOS030230308 |
| AS-35061 |
| BCP9000866 |
| C27H26ClF3N6O3 |
| CHEMBL2105695 |
| CS-2311 |
| D09974 |
| ethyl (2S)-2-amino-3-[4-[2-amino-6-[(1R)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]pyrimidin-4-yl]phenyl]propanoate |
| EX-A322 |
| FT-0771085 |
| GTPL9490 |
| HY-13055A |
| J-524318 |
| KB-78222 |
| KS-0000067M |
| LX 1032 |
| LX 1606 |
| LX-1606 |
| LX1606 |
| LX1606 /LX-1606 |
| MDSQOJYHHZBZKA-GBXCKJPGSA-N |
| MolPort-028-720-356 |
| NCGC00390241-01 |
| RL00164 |
| SB18006 |
| SCHEMBL610588 |
| TELOTRISTAT ETHYL |
| Telotristat ethyl (USAN) |
| Telotristat ethyl [USAN] |
| Telotristat ethyl; (2S)-2-Amino-3-[4-[2-amino-6-[[(1R)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethyl]oxy]pyrimidin-4-yl]phenyl]propionic acid ethyl ester |
| Telotristat ethyl|||4-[2-amino-6-[(1R)-1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]-4-pyrimidinyl]-L-phenylalanine, ethyl ester |
| UNII-8G388563M7 |
| Xermelo (TN) |
| ZINC43205655 |
US Patents and Regulatory Information for XERMELO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharms Inc | XERMELO | telotristat etiprate | TABLET;ORAL | 208794-001 | Feb 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Lexicon Pharms Inc | XERMELO | telotristat etiprate | TABLET;ORAL | 208794-001 | Feb 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Lexicon Pharms Inc | XERMELO | telotristat etiprate | TABLET;ORAL | 208794-001 | Feb 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Lexicon Pharms Inc | XERMELO | telotristat etiprate | TABLET;ORAL | 208794-001 | Feb 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XERMELO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 200922934 | Start Trial |
| South Korea | 20090087916 | Start Trial |
| Uruguay | 31364 | Start Trial |
| Norway | 20092639 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for XERMELO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2091940 | 11/2018 | Austria | Start Trial | PRODUCT NAME: TELOTRISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARER ESTER, ODER EIN SALZ DAVON, INSBESONDERE TELOTRISTATETHYL, INSBESONDERE DAS HIPPURATSALZ VON TELOTRISTATETHYL; REGISTRATION NO/DATE: EU/1/17/1224 (MITTEILUNG) 20170920 |
| 2091940 | CA 2018 00011 | Denmark | Start Trial | PRODUCT NAME: TELOTRISTAT OR A PHARMACEUTICALLY ACCEPTABLE ESTER, OR A SALT THEREOF, INPARTICULAR TELOTRISTAT ETHYL, MORE PARTICULARLY HIPPURATE SALT OF TELOTRISTAT ETHYL; REG. NO/DATE: EU/1/17/1224 20170920 |
| 2091940 | 18C1009 | France | Start Trial | PRODUCT NAME: TELOTRISTAT OU L'UN DE SES ESTERS PHARMACEUTIQUEMENT ACCEPTABLES,OU L'UN DE LEURS SELS,EN PARTICULIER LE TELOTRISTAT D'ETHYLE ET PLUS PARTICULIEREMENT L'HIPPURATE DE TELOTRISTAT D'ETHYLE; REGISTRATION NO/DATE: EU/1/17/1224 20170920 |
| 2091940 | 1890014-2 | Sweden | Start Trial | PRODUCT NAME: TELOTRISTAT OR A PHARMACEUTICALLY ACCEPTABLE ESTER, OR A SALT THEREOF, IN PARTICULARLY TELOTRISTAT ETHYL, MORE PARTICULARLY HIPPURATE SALT OF TELOTRISTAT ETHYL; REG. NO/DATE: EU/1/17/1224 20170920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
